<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04232423</url>
  </required_header>
  <id_info>
    <org_study_id>162/2562</org_study_id>
    <nct_id>NCT04232423</nct_id>
  </id_info>
  <brief_title>Olanzapine for Chemotherapy-induced Nausea and Vomiting Prophylaxis</brief_title>
  <acronym>OLN-EME</acronym>
  <official_title>Efficacy and Dosage of Olanzapine for Chemotherapy-induced Nausea and Vomiting Prophylaxis in Women With Gynecologic Cancers Receiving Carboplatin-based Regimen : a Double-blind, Placebo-controlled, Randomized Crossover Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rajavithi Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rajavithi Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate that olanzapine can reduced side effect about nausea and vomiting in women
      with gynecologic cancers receiving carboplatin-based regimen by using olanzapine and placebo
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A double-blind, placebo-controlled, randomized crossover trial
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 1, 2020</start_date>
  <completion_date type="Anticipated">March 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>A Double-Blind, Placebo-Controlled, Randomized Crossover Trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete response rate of chemotherapy-induced nausea and vomiting prophylaxis</measure>
    <time_frame>5 days after chemotherapeutic administration</time_frame>
    <description>No breakthrough vomiting and no using rescue therapy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Episodes of vomiting</measure>
    <time_frame>5 days after chemotherapeutic administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of nausea</measure>
    <time_frame>5 days after chemotherapeutic administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of rescue drug</measure>
    <time_frame>5 days after chemotherapeutic administration</time_frame>
    <description>using of rescue anti-emetic medication</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life associated with nausea and vomiting measured using Functional Living Index-Emesis (FILE)</measure>
    <time_frame>5 days after chemotherapeutic administration</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Complete Response Rate to Chemotherapy-induced Nausea and Vomiting Prophylaxis</condition>
  <arm_group>
    <arm_group_label>OLN 0-5-10</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo tablet in chemotherapy cycle 1, olanzapine 5 mg tablet in chemotherapy cycle 2, and olanzapine 10 mg tablet in chemotherapy cycle 3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>OLN 5-10-0</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Olanzapine 5 mg tablet in chemotherapy cycle 1, olanzapine 10 mg tablet in chemotherapy cycle 2, and placebo tablet in chemotherapy cycle 3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>OLN 10-0-5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Olanzapine10 tablet in chemotherapy cycle 1, placebo tablet in chemotherapy cycle 2, and olanzapine 5 mg tablet in chemotherapy cycle 3</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olanzapine 10 Mg ORAL TABLET</intervention_name>
    <description>Olanzapine 10 mg orally, ondansetron 8 mg intravenously, and dexamethazone 8 mg intravenously 30 minutes before chemotherapeutic administration (day 1)
Olanzapine 10 mg orally daily and dexamethazone 8 mg orally daily on day 2, 3, 4</description>
    <arm_group_label>OLN 0-5-10</arm_group_label>
    <arm_group_label>OLN 10-0-5</arm_group_label>
    <arm_group_label>OLN 5-10-0</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olanzapine 5 Mg ORAL TABLET</intervention_name>
    <description>Olanzapine 5 mg orally, ondansetron 8 mg intravenously, and dexamethazone 8 mg intravenously 30 minutes before chemotherapeutic administration (day 1)
Olanzapine 5 mg orally daily and dexamethazone 8 mg orally daily on day 2, 3, 4</description>
    <arm_group_label>OLN 0-5-10</arm_group_label>
    <arm_group_label>OLN 10-0-5</arm_group_label>
    <arm_group_label>OLN 5-10-0</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo ORAL TABLET</intervention_name>
    <description>Placebo 1 tab orally, ondansetron 8 mg intravenously, and dexamethazone 8 mg intravenously 30 minutes before chemotherapeutic administration (day 1)
Placebo 1 tab orally daily and dexamethazone 8 mg orally daily on day 2, 3, 4</description>
    <arm_group_label>OLN 0-5-10</arm_group_label>
    <arm_group_label>OLN 10-0-5</arm_group_label>
    <arm_group_label>OLN 5-10-0</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women with gynecological cancer receiving carboplatin-based chemotherapeutic regimen

          -  ECOG performance status 0-1

          -  Normal bone marrow, liver, and renal functions

          -  Can speak and write in Thai language

        Exclusion Criteria:

          -  Women with nausea or vomiting prior to chemotherapeutic administration

          -  Pregnant women

          -  Women with active infection

          -  Women with bowel obstruction

          -  Women with symptomatic brain metastases

          -  Women who received dopamine receptor antagonists within 1 week before chemotherapeutic
             administration

          -  Women who received corticosteroid within 1 week before chemotherapeutic administration

          -  Women with past history of chemotherapy or radiotherapy

          -  Women with psychiatric disorders

          -  Women with poor controlled diabetes mellitus

          -  Women who received anticonvulsant medication

          -  Women with history of neuroleptic malignant syndrome

          -  Women with history of olanzapine allergy

          -  Women with history of lactose intolerance
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>January 14, 2020</study_first_submitted>
  <study_first_submitted_qc>January 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 18, 2020</study_first_posted>
  <last_update_submitted>January 14, 2020</last_update_submitted>
  <last_update_submitted_qc>January 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rajavithi Hospital</investigator_affiliation>
    <investigator_full_name>Charuwan Manmee</investigator_full_name>
    <investigator_title>Division of Research and Technology Assessment</investigator_title>
  </responsible_party>
  <keyword>Olanzapine</keyword>
  <keyword>Chemotherapy-induced nausea and vomiting</keyword>
  <keyword>Carboplatin</keyword>
  <keyword>Gynecologic cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nausea</mesh_term>
    <mesh_term>Vomiting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Olanzapine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

